Isagro sales decreased 11% in Q1 2018

Isagro achieved a period historically not representative of the full-year results due to the seasonal nature of the business of the Group in the first quarter of 2018. Isagro sales decreased 10.6% to 42.2 Euro million in the first quarter 2018, and EBITDA dropped by 39.2% to 4.5 million.

Outlook:

The 2018 full-year results are expected to improve versus 2017 thanks mostly to growth of Isagro Asia and higher initial revenues from new M/L Agreements. 
 
In the mid-term (2020/2021) Isagro confirms the target of around 200 Euro million revenues at a consolidated level, based on the implementation of its Strategic Guidelines:
1. discovery of new molecules by itself;
2. development of proprietary molecules through agreements with Third Parties;
3. M/L Agreements to widen the commercial exploitation of its own products;
4. growth in the Biosolutions business;
5. expansion of its own global commercial organization;
6. selective actions of growth through acquisitions